Pharmaceutical Product Approval Trends, 2007: Key market benchmarks and strategic insights

“Among the 23 new pharmaceutical products approved in the first half of 2007, there were 22 small molecule pharmaceutical drugs and one monoclonal antibody.”

Pharmaceutical Product Approval Trends 2007: Key market benchmarks and strategic insights presents a detailed analysis of the new pharmaceutical products approved globally.

The 120-page report outlines the key therapeutic markets, significant pharmaceutical entities which were approved, assesses major companies and identifies key trends and opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting.

• The US and Europe accounted for 90% of the 2006 global sales of new medicines launched between 2002 and 2006
• More than 70% of all new pharmaceutical products approved between 2004 and 2006 received an initial approval in the US
• A total of 38 new pharmaceutical products were approved in the US in 2006 and a total of 31 new pharmaceutical products were approved in Europe in the same year.
• The leading companies by number of new drug approvals in the first half of 2007 were GSK with three and Wyeth with two.
• The leading therapy areas for new drug approvals in 2007 were genito-urinary system and sex hormones (ATC code G) and nervous system (ATC code N) with four.
• The leading generic product by number of applicant approvals in 2006 was meloxicam, which was approved for 21 different companies.

• Comprehensive overview of the global approval trends with sections on U.S and E.U approval trends.
• Identifies the top 11 products approved in 2006 including Exforge, Prezista, Gardasil, Invega, Acomplia and Chantix.
• Therapy area trends for antineoplastic and immunomodulating agents, alimentary tract and metabolism, nervous system, anti-infectives for systemic use, cardiovascular system, genitourinary system and sex hormones as well as sensory organs.
• Detailed profiles of major companies (AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson and Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi-Aventis Wyeth.)
• Analysis of key company trends for leading companies by current and prospective new product approvals. (GlaxoSmithKline,Wyeth, Novartis, Shire, Cephalon and Roche.)
• 120 pages long, with 66 figures and 40 tables to illustrate the market trends.
• Coverage US, Europe and Japan

• 1. Benchmark your portfolio against key market trends and forecasts in order to plan better for success.
• 2. Identify key areas of pharmaceutical market growth and key opportunities for delivering successful sales growth over the next five years.
• 3. Support internal planning and decision-making with an external perspective founded on detailed analysis and transparent market forecasts.

The report methodology provides a detailed but transparent analysis of key pharmaceutical market trends, including key markets, therapy areas, products and companies. It compares new product approvals in 2006 with data from the previous two years.

All data used in outlining historical trends is clearly sourced within the report and any data limitations or additional assumptions are explicitly detailed within the text of the report. Future market forecasts are projected based on both historical trends and future expectations over market conditions and events. The assumptions used to form the basis of key market forecasts are outlined in detail within the text of the report.